In addition to glycaemic control, there are several hypothesized mechanisms behind the effectiveness of SGLT-2 inhibitors in reducing mortality and morbidity associated with HF [17,18] and type 2 diabetes mellitus [19,20]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.